Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
58 hedge funds and large institutions have $577M invested in Centessa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
428% more call options, than puts
Call options by funds: $169K | Put options by funds: $32K
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
23% more capital invested
Capital invested by funds: $470M → $577M (+$107M)
18% more funds holding
Funds holding: 49 → 58 (+9)
0.26% less ownership
Funds ownership: 74.52% → 74.25% (-0.26%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$10.6M |
| 2 |
Morgan Stanley
New York
|
+$9.86M |
| 3 |
AG
Artal Group
Luxembourg
|
+$6.79M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$1.99M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$4.99M |
| 2 |
SCM
Sio Capital Management
New York
|
-$4.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.2M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$1.93M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.91M |
CNTA Hedge Fund Activity: Q4 2023 in Review
58 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q4 2023, worth a combined $577M — up 23% from $470M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CNTA positions and 2 closed out — a net gain of 10 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $10.6M. The largest seller was Boxer Capital, exiting entirely with an estimated $4.99M sold.
- 58 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q4 2023, up from 49 in Q3 2023.
- Funds reported $577M of Centessa Pharmaceuticals stock for Q4 2023, up 23% quarter-over-quarter.
- 12 funds opened new Centessa Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +10 holders.
- The largest Centessa Pharmaceuticals buyer in Q4 2023 was Octagon Capital Advisors, an estimated $10.6M added.
- The largest Centessa Pharmaceuticals seller in Q4 2023 was Boxer Capital, an estimated $4.99M sold.
Based on aggregated 13F filings for Q4 2023.